These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11483881)

  • 41. Chronic therapy with an ET(A/B) receptor antagonist in conscious dogs during progression of congestive heart failure. Intracellular Ca(2+) regulation and nitric oxide mediated coronary relaxation.
    Shen YT; Buie PS; Lynch JJ; Krause SM; Ma XL
    Cardiovasc Res; 2000 Nov; 48(2):332-45. PubMed ID: 11054479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
    Mulder P; Boujedaini H; Richard V; Derumeaux G; Henry JP; Renet S; Wessale J; Opgenorth T; Thuillez C
    Circulation; 2000 Aug; 102(5):491-3. PubMed ID: 10920058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart.
    Sakai S; Miyauchi T; Sakurai T; Kasuya Y; Ihara M; Yamaguchi I; Goto K; Sugishita Y
    Circulation; 1996 Mar; 93(6):1214-22. PubMed ID: 8653844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of the endothelin system to the renal hypoperfusion associated with experimental congestive heart failure.
    Friedrich EB; Muders F; Luchner A; Dietl O; Riegger GA; Elsner D
    J Cardiovasc Pharmacol; 1999 Oct; 34(4):612-7. PubMed ID: 10511139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of endothelin receptor antagonism on acute lung injury induced by chlorine gas.
    Wang J; Oldner A; Winskog C; Edston E; Walther SM
    Crit Care Med; 2006 Jun; 34(6):1731-7. PubMed ID: 16625121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure.
    Wada A; Tsutamoto T; Fukai D; Ohnishi M; Maeda K; Hisanaga T; Maeda Y; Matsuda Y; Kinoshita M
    J Am Coll Cardiol; 1997 Nov; 30(5):1385-92. PubMed ID: 9350944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock.
    Fenhammar J; Andersson A; Frithiof R; Forestier J; Weitzberg E; Sollevi A; Hjelmqvist H
    Acta Anaesthesiol Scand; 2008 Nov; 52(10):1385-93. PubMed ID: 19025532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of dual ET(A)/ET(B)-receptor blockade on coronary responses to treadmill exercise in dogs.
    Takamura M; Parent R; Cernacek P; Lavallée M
    J Appl Physiol (1985); 2000 Nov; 89(5):2041-8. PubMed ID: 11053360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252.
    Bauersachs J; Braun C; Fraccarollo D; Widder J; Ertl G; Schilling L; Kirchengast M; Rohmeiss P
    J Hypertens; 2000 Oct; 18(10):1507-14. PubMed ID: 11057440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the endothelin-1 receptor antagonist tezosentan on renal blood flow and diuresis during prolonged increased intra-abdominal pressure.
    Gudmundsson FF; Viste A; Myking OL; Grong K; Bostad L; Svanes K
    J Surg Res; 2003 Nov; 115(1):33-40. PubMed ID: 14572770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
    Bishara B; Abu-Saleh N; Awad H; Ghrayeb N; Goltsman I; Aronson D; Khamaysi I; Assady S; Armaly Z; Haddad S; Haddad E; Abassi Z
    Eur J Heart Fail; 2012 Oct; 14(10):1104-11. PubMed ID: 22740510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
    Lüscher TF; Enseleit F; Pacher R; Mitrovic V; Schulze MR; Willenbrock R; Dietz R; Rousson V; Hürlimann D; Philipp S; Notter T; Noll G; Ruschitzka F;
    Circulation; 2002 Nov; 106(21):2666-72. PubMed ID: 12438291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function.
    Wilhelm SM; Stowe NT; Robinson AV; Schulak JA
    Transplantation; 2001 Jan; 71(2):211-6. PubMed ID: 11213061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
    Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
    Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endothelin-1 blockade corrects mesenteric hypoperfusion in a porcine low cardiac output model.
    Burgener D; Laesser M; Treggiari-Venzi M; Oi Y; Jolliet P; Strasser S; Hadengue A; Aneman A
    Crit Care Med; 2001 Aug; 29(8):1615-20. PubMed ID: 11505140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal and hormonal effects of systemic nitric oxide inhibition in patients with congestive heart failure and in healthy control subjects.
    Bech JN; Starklint J; Bentzen H; Nyvad O; Pedersen EB
    J Card Fail; 2013 Nov; 19(11):776-85. PubMed ID: 24263123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
    Richer C; Fornes P; Cazaubon C; Domergue V; Nisato D; Giudicelli JF
    Cardiovasc Res; 1999 Jan; 41(1):100-8. PubMed ID: 10325957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
    Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
    Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
    Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
    Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.